Outcomes in older patients with acute myeloid leukemia (AML) have historically been poor.
Given advances in low‐intensity therapy (LIT) and stem cell transplantation (SCT), we …

The 5-year overall survival (OS) for older (age older than 60 years) adult patients diagnosed
with non-acute promyelocytic leukemia who have acute myeloid leukemia (AML) is only …

Objectives The majority of patients with acute myeloid leukemia (AML) are aged 70 and
over. However, there is uncertainty about how and whether older patients with AML should …

Most patients with newly diagnosed acute myeloid leukemia (AML) are at least age 65 and
continue to have short survival, with many patients receiving no specific anti-AML therapy …

Abstract Acute Myeloid Leukemia is a clonal proliferative disorder whose incidence
increases with age. While studies have shown that the elderly medically unfit patients have …

BACKGROUND Contemporary treatment protocols for adult acute myeloid leukemia (AML)
are age‐specific, and older patients are generally treated less intensively than younger …

Several criteria to define fitness for induction chemotherapy in elderly acute myeloid
leukemia (AML) have been proposed; however, no studies have reported outcomes …

Acute myeloid leukemia (AML) is a disease of the elderly, with the majority of patients
diagnosed in their 6th and 7th decade of life. Older patients with AML are less likely to …

Acute myeloid leukemia (AML) is predominantly a disease of older adults, with a median
age at diagnosis of over 65 years. AML in older adults differs biologically and clinically from …

Standard therapy for acute myeloid leukemia (AML) has long consisted of intensive
chemotherapy followed by allogeneic hematopoietic stem cell transplant. Older individuals …